Platelet aggregation inhibition with ticlopidine in the treatment of stroke.
Zauner
C
C
Funk
G C
GC
Birnbacher
R
R
D000208:Acute Disease; D003422:Critical Care / Q000379:methods; D003875:Drug Eruptions / Q000209:etiology; D016903:Drug Monitoring; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced; D018048:Receptors, Purinergic P2 / Q000187:drug effects; D020521:Stroke / Q000188:drug therapy*; D013988:Ticlopidine / Q000009:adverse effects / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D018048:Receptors, Purinergic P2; D013988:Ticlopidine